Bio-Genome Protein Drug Development
New Drug Discovery
Raphe's mission as a peptide pharmacologist is to discover modifications in the nucleotide structure that will effectively modify the human genome, thereby elongating telomeres to enhance longevity and increase the average lifespan of humans to 140 years, while maintaining the youthful internal organs that sustain life.
This is a call to all pharmaceutical investors and Biologic and genetic engineers to join us, put our minds together, and develop a peptide drug or protein moiety for successful human genome modification, which will be used in extending lifespan. We're exploring short protein synthesis that could modify the human genome, as well as stem cell modification of the amino acid side chains.
If you have a passion for the future of humankind, please join Raphe. Together, we can make a difference. Long clinical trials will be involved, but the effort will ultimately be worthwhile. We will need scientists in this field to examine the in vitro behaviors of different cells when this new protein-based drug is introduced. The purpose is not gene editing and will not be tailored towards curing any genetic disease, but rather to introduce modified short protein moieties into the human genome that will halt the body's free radical oxidative process and make tissues resistant to oxidation. We will be exploring science research-based short proteins and modified amino acids that could be added to the human genome to stabilize the cells and halt the oxidative aging process, keep the cells, organs, and tissues constantly at their optimum health and function for a more extended period, twice what we currently have now as human lifespan.
Are you interested? Raphe can be reached at: PeptideNCEs@AmWiner.Com